- Home
- KRRO vs CDLX Comparison
KRRO vs CDLX Comparison
Compare KRRO & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- CDLX
- Stock Information
- Founded
- KRRO 2014
- CDLX 2008
- Country
- KRRO United States
- CDLX United States
- Employees
- KRRO N/A
- CDLX N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- CDLX Computer Software: Programming Data Processing
- Sector
- KRRO Health Care
- CDLX Technology
- Exchange
- KRRO Nasdaq
- CDLX Nasdaq
- Market Cap
- KRRO 101.4M
- CDLX 98.2M
- IPO Year
- KRRO 2019
- CDLX 2018
- Fundamental
- Price
- KRRO $12.35
- CDLX $1.74
- Analyst Decision
- KRRO Strong Buy
- CDLX Hold
- Analyst Count
- KRRO 7
- CDLX 5
- Target Price
- KRRO $85.67
- CDLX $3.50
- AVG Volume (30 Days)
- KRRO 203.4K
- CDLX 696.9K
- Earning Date
- KRRO 08-12-2025
- CDLX 08-06-2025
- Dividend Yield
- KRRO N/A
- CDLX N/A
- EPS Growth
- KRRO N/A
- CDLX N/A
- EPS
- KRRO N/A
- CDLX N/A
- Revenue
- KRRO $4,821,000.00
- CDLX $272,588,000.00
- Revenue This Year
- KRRO $65.08
- CDLX N/A
- Revenue Next Year
- KRRO N/A
- CDLX $5.51
- P/E Ratio
- KRRO N/A
- CDLX N/A
- Revenue Growth
- KRRO N/A
- CDLX N/A
- 52 Week Low
- KRRO $10.29
- CDLX $1.22
- 52 Week High
- KRRO $98.00
- CDLX $9.48
- Technical
- Relative Strength Index (RSI)
- KRRO 41.55
- CDLX 47.65
- Support Level
- KRRO $11.50
- CDLX $1.50
- Resistance Level
- KRRO $16.86
- CDLX $2.18
- Average True Range (ATR)
- KRRO 1.50
- CDLX 0.17
- MACD
- KRRO 0.01
- CDLX 0.00
- Stochastic Oscillator
- KRRO 31.35
- CDLX 35.29
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About CDLX Cardlytics Inc.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.